Structure of Clofibric acid
CAS No.: 882-09-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Clofibric acid is an agonist of PPARα and can act as a hypolipidemic agent.
Synonyms: Chlorofibrinic acid; NSC 1149; CCRIS9254 Chlorfibrinic acid
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 882-09-7 |
| Formula : | C10H11ClO3 |
| M.W : | 214.65 |
| SMILES Code : | CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O |
| Synonyms : |
Chlorofibrinic acid; NSC 1149; CCRIS9254 Chlorfibrinic acid
|
| MDL No. : | MFCD00004192 |
| InChI Key : | TXCGAZHTZHNUAI-UHFFFAOYSA-N |
| Pubchem ID : | 2797 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302 |
| Precautionary Statements: | P280-P305+P351+P338 |
| Description |
Clofibric acid (Chlorofibrinic acid), the active metabolite derived from lipid regulators such as Clofibrate, Etofibrate, and Etofyllinclofibrate, acts as a PPARα agonist and is known for its hypolipidemic effects. Additionally, Clofibric acid is used as an herbicide[1].[2].[3].
|
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT00144937 | Peripheral Arterial Disease ... More >> Hypercholesterolemia Hypertension Diabetes Mellitus Smoking Less << | Phase 4 | Unknown | - | Spain ... More >> Hospital de Sabadell Sabadell, Barcelona, Spain, 08208 Less << |
| NCT03031821 | Prostate Cancer ... More >> Metabolic Syndrome Less << | Phase 3 | Not yet recruiting | June 1, 2023 | Canada, British Columbia ... More >> BC Cancer Agency - Vancouver Cancer Centre Not yet recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Bernie Eigl, MD 604-877-6000 bernie.eigl@bccancer.bc.ca Principal Investigator: Bernie Eigl, MD Less << |
| NCT01047501 | Hypertriglyceridemia | Phase 3 | Completed | - | - |
| NCT01047683 | Hypertriglyceridemia | Phase 3 | Completed | - | - |
| NCT03058913 | - | Recruiting | December 2025 | United States, Illinois ... More >> Outpatient Endovascular Interventional Society (OEIS) Recruiting Hoffman Estates, Illinois, United States, 60169 Contact: Jeff Carr 903-521-6004 jeffcarr@me.com Less << | |
| NCT01529424 | Hypertriglyceridemia | Phase 2 | Completed | - | United States, North Carolina ... More >> Farmville Internal Medicine Farmville, North Carolina, United States, 27828 Mark R. Cervi Greenville, North Carolina, United States, 27834 Physicians East, Quadrangle Medical Specialists Greenville, North Carolina, United States, 27834 Carolina East Family Medicine Greenville, North Carolina, United States, 27858 Eastern Carolina Physicians Kinston, North Carolina, United States, 28504 Natalie A Doyle, MD PA Wilson, North Carolina, United States, 27893 Canada, Quebec Isis Investigational site Chicoutimi, Quebec, Canada Less << |
| NCT01492361 | Cardiovascular Diseases | Phase 3 | Completed | - | - |
| NCT02282423 | Diabetes Obes... More >>ity Less << | Not Applicable | Terminated(PI job change) | - | United States, Arizona ... More >> Mayo Clinic Scottsdale, Arizona, United States, 85259 Less << |
| NCT00309712 | Type II Diabetes Mellitus ... More >> Mixed Dyslipidemia Less << | Not Applicable | Completed | - | United States, Utah ... More >> McKay Dee Hospital Ogden, Utah, United States, 84403 LDS Hospital Salt Lake City, Utah, United States, 84143 Less << |
| NCT01022450 | - | Unknown | - | Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 10051 Contact: Kwan-Dun Wu, MD, PhD 886-2-23123456 ext 65014 kdwu@ntuh.gov.tw Principal Investigator: Fe-Lin L Wu, MSCP, PhD Sub-Investigator: Kwan-Dun Wu, MD, PhD Less << | |
| NCT02886299 | Fenofibrate/Simvastatin Compar... More >>ison Less << | Phase 4 | Completed | - | - |
| NCT03430284 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | December 31, 2020 | China, Shandong ... More >> Shandong Provincial Hospital Not yet recruiting Jinan, Shandong, China, 250021 Contact: Shanshan Shao +8653168776094 shaoshanshan11@126.com Shandong Provincial Hospital Recruiting Jinan, Shandong, China Less << |
| NCT00542178 | Diabetic Retinopathy | Phase 3 | Completed | - | United States, Minnesota ... More >> The Berman Center for Clinical Research Minneapolis, Minnesota, United States, 55404 United States, New York Columbia University New York, New York, United States, 10032 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106-4951 United States, Tennessee Veterans Affairs Memphis, Tennessee, United States, 38104-2193 United States, Washington University of Washington Seattle, Washington, United States, 98109 Canada, Ontario McMaster University Hamilton, Ontario, Canada, L8L 2X2 Less << |
| NCT00535925 | Diabetic Nephropathy | Phase 4 | Unknown | September 2012 | Italy ... More >> Department of Clinical and Experimental Medicine, Second University of Naples Naples, Italy, I-80131 Less << |
| NCT00542178 | - | Completed | - | - | |
| NCT02965911 | Primary Biliary Cirrhosis | Phase 1 Phase 2 | Recruiting | January 2019 | China ... More >> Beijing 302 hospital Recruiting Beijing, China, 100039 Contact: Zhengsheng Zou, Dr. Principal Investigator: Zhengsheng Zou, Dr. Less << |
| NCT03323788 | - | Recruiting | August 1, 2018 | United States, Arizona ... More >> The University of Arizona Recruiting Tucson, Arizona, United States, 85724 Contact: Oscar Parra, MADM 520-626-6485 oscardp@email.arizona.edu Principal Investigator: Lawrence Mandarino, PhD Less << | |
| NCT03649269 | Hypertriglyceridemia | Not Applicable | Completed | - | - |
| NCT02863185 | Chronic Kidney Disease | Phase 4 | Recruiting | December 2019 | Korea, Republic of ... More >> Won Suk An Recruiting Busan, Korea, Republic of, 602-715 Contact: Won Suk An, M.D., Ph.D. +82-51-240-2811 anws@dau.ac.kr Dong-A University Not yet recruiting Busan, Korea, Republic of, 602715 Contact: Su Mi Lee, MD +822405549 promise131@hanmail.net Less << |
| NCT00451464 | - | Completed | - | Taiwan ... More >> Pan-Chyr Yang Taipei, Taiwan, 100 Less << | |
| NCT03449784 | - | Recruiting | May 1, 2041 | France ... More >> Uhmontpellier Recruiting Montpellier, France, 34295 Contact: cyril BREUKER c-breuker@chu-montpellier.fr Less << | |
| NCT01515241 | Heterozygous Familial Hypercho... More >>lesterolemia Less << | Phase 2 | Completed | - | Canada, Quebec ... More >> Montreal Heart Institute Montreal, Quebec, Canada, H1T1C8 Less << |
| NCT00116636 | HIV Infections | Phase 2 | Completed | - | United States, Texas ... More >> Therapeutic Concepts, P.A. Houston, Texas, United States, 77004 Less << |
| NCT03345901 | Diabetic Retinopathy ... More >> Diabetic Macular Edema Less << | Phase 3 | Recruiting | January 2023 | - |
| NCT00934219 | Hypertriglyceridemia | Phase 4 | Unknown | December 2012 | United States, Ohio ... More >> Jewish Hospital Cholesterol Center Recruiting Cincinnati, Ohio, United States, 45229 Less << |
| NCT00362934 | Hyperlipidemia | Phase 3 | Completed | - | - |
| NCT00349375 | Hyperlipidemia | Phase 3 | Completed | - | - |
| NCT02548832 | Mixed Dyslipidemia | Phase 2 | Unknown | July 2016 | Mexico ... More >> Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara Recruiting Guadalajara, Jalisco, Mexico, 44340 Contact: Esperanza Martínez Abundis, PhD Science (33) 1058-5200 ext 34211 esperanzamartnezabundi@yahoo.com Less << |
| NCT01101503 | Endothelial Dysfunction | Phase 2 | Recruiting | December 2020 | China, Hubei ... More >> Department of Endocrinology Recruiting Wuhan City, Hubei, China, 430070 Contact: Xiang Guangda, MD, Ph D +862768878410 Guangda64@hotmail.com Principal Investigator: Xiang Guangda, MD, Ph D Less << |
| NCT00362206 | Hyperlipidemia | Phase 3 | Completed | - | - |
| NCT01462877 | - | Completed | - | - | |
| NCT01025492 | Dyslipidemia | Phase 4 | Terminated(Collaborator/corpor... More >>ate sponsor withdrew funding and permission to continue.) Less << | - | United States, Utah ... More >> University of Utah Salt Lake City, Utah, United States, 84108 Less << |
| NCT00352183 | Cardiovascular Diseases | Phase 3 | Completed | - | - |
| NCT01148004 | HIV Fenofibra... More >>te Protease Inhibitors Hypertriglyceridemia Glucuronosyltransferase Less << | Phase 1 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
| NCT00037401 | - | Completed | - | - | |
| NCT01462877 | Dyslipidemias ... More >> Cardiovascular Diseases Hypertriglyceridemia Less << | Phase 4 | Completed | - | China ... More >> Site Reference ID/Investigator# 64695 Xiamen, China, 36100 Less << |
| NCT01477944 | - | Completed | - | - | |
| NCT01602913 | - | Completed | - | - | |
| NCT01674712 | Dyslipidemia | Phase 3 | Completed | - | - |
| NCT00965315 | - | - | - | - | |
| NCT01385020 | Healthy Subjects | Phase 4 | Completed | - | Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less << |
| NCT01674712 | - | Completed | - | - | |
| NCT01654731 | PBC | Phase 3 | Completed | - | France ... More >> Hepatology department - Hopital Saint Antoine Paris, France, 75012 Less << |
| NCT00728910 | Dyslipidemia | Phase 2 | Completed | - | United States, Pennsylvania ... More >> CTRC (Clinical Translational Research Center) Philadelphia, Pennsylvania, United States, 19104 Less << |
| NCT00728910 | - | Completed | - | - | |
| NCT03110432 | - | Recruiting | February 16, 2021 | Germany ... More >> Medizinische Klinik und Poliklinik III Recruiting Dresden, Germany Contact: Andreas Birkenfeld, MD Less << | |
| NCT00458055 | Coronary Arteriosclerosis ... More >> Hypoalphalipoproteinemias Genetic Diseases, Inborn Less << | Not Applicable | Completed | - | Canada, Quebec ... More >> MUHC-Royal Victoria Hospital Montreal, Quebec, Canada, H3A 1A1 Less << |
| NCT00156169 | Low HDL Cholesterol | Phase 3 | Completed | - | - |
| NCT02530827 | - | Completed | - | - | |
| NCT00491400 | Diabetes Mellitus ... More >> Metabolic Syndrome Less << | Not Applicable | Terminated(Insufficient enroll... More >>ment) Less << | - | United States, Massachusetts ... More >> Boston Medical Center Boston, Massachusetts, United States, 02118 Less << |
| NCT00243672 | Atherosclerosis | Phase 4 | Withdrawn(The study chair chan... More >>ged his employment, the realization of the study was not possible) Less << | - | - |
| NCT01025492 | - | Terminated(Collaborator/corpor... More >>ate sponsor withdrew funding and permission to continue.) Less << | - | - | |
| NCT03586674 | Chronic Cholestasis | Phase 2 | Completed | - | Egypt ... More >> Dr. Yassin Abdel Ghaffar Charity Center For Liver Diseases & Researches Cairo, Nasr City, Egypt National liver istitute Shibīn Al Kawm, Egypt Less << |
| NCT01527318 | Neutral Lipid Storage Disease | Phase 4 | Completed | - | Netherlands ... More >> Maastricht University Medical Center Maastricht, Limburg, Netherlands, 6200MD Less << |
| NCT00491400 | - | Terminated(Insufficient enroll... More >>ment) Less << | - | - |
Tags: Clofibric acid | Chlorofibrinic acid | Bile Acid | Carboxylic Acids | PPAR | Steroids | Cell Cycle | Vitamin D Related/Nuclear Receptor | Cancer Stem Cells | PPAR Signaling Pathway | Organic Building Blocks | 882-09-7
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


